Scholarlink

Background <p>Icotrokinra represents a novel therapeutic approach that may address limitations associated with current injectable biologic therapies, including storage requirements and self-administration complexity, and may benefit patients who have needle aversion.</p> Methods <p>We included five randomized controlled trials (RCTs) comparing icotrokinra with placebo. PubMed, Embase, and Cochrane CENTRAL were systematically searched from inception to November 2025. Primary outcomes included the proportion of patients achieving an Investigator’s Global Assessment (IGA) score of 0 (clear skin) or 1 (minimal disease) and an IGA score of 0 at weeks 4,&#xa0;8 and 16; a scalp-specific IGA (ss-IGA) score of 0 or 1 at weeks 8 and 16; and at least 75%, 90%, and 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI 75, PASI 90, and PASI 100) at weeks 4, 8 and 16. Patient-reported outcomes included the Psoriasis Symptoms and Signs Diary (PSSD) symptom score of 0 at weeks 8 and 16. Safety outcomes were also assessed. Secondary analyses involved subgroup evaluations of icotrokinra 200&#xa0;mg once daily.</p> Results <p>Across five included RCTs, 1509 (54.77%) patients received icotrokinra. Icotrokinra significantly increased the likelihood of achieving an IGA score of 0&#xa0;or1 at week 4 (OR 7.08; 95%&#xa0;CI 4.33 to 11.55; <i>P</i> &lt; 0.001), week 8 (OR 13.29; 95% CI 9.19 to 19.21; <i>P</i> &lt; 0.001), and week 16 (OR 18.76; 95% CI 13.88 to 25.36; <i>P</i> &lt; 0.001).&#xa0;Consistent findings were observed for PASI 90 at week 4 (OR 10.30; 95% CI 2.54 to 41.81; <i>P</i> = 0.003), week 8 (OR 28.65; 95%&#xa0;CI 11.60 to 70.75; <i>P</i> &lt; 0.001),and week 16 (OR 27.14; 95% CI 16.66 to 44.22; <i>P</i> &lt; 0.001). For high-impact, difficult-to-treat sites, icotrokinra significantly increased the likelihood of achieving a ss-IGA score of 0&#xa0;or&#xa0;1 at week 8 (OR 7.56; 95% CI 5.73 to 9.96; <i>P</i> &lt; 0.001) and week 16 (OR 9.61; 95% CI 7.00 to 13.20; <i>P</i> &lt; 0.001). Neither the incidence of serious adverse events (OR 0.63; 95% CI 0.29 to 1.34; <i>P</i> = 0.23) nor malignancy (OR 2.61; 95%&#xa0;CI 0.30 to 22.56; <i>P</i> = 0.82) was significantly different between groups.</p> Conclusions <p>Icotrokinra demonstrated a favorable short-term efficacy and an acceptable safety profile compared to placebo in patients with moderate-to-severe plaque psoriasis, including meaningful responses in high-impact sites, supporting its potential as a promising oral therapeutic option. Long-term studies and comparative trials against current injectable biologic therapies are warranted to better define its place in the therapeutic armamentarium.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A novel oral interleukin-23 receptor antagonist peptide, icotrokinra, for moderate-to- severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials

  • 期刊论文

  • 发表日期：

    2026年3月3日

查看全文
  • Martin Cevallos-Cueva,
  • Chinenye Onejeme,
  • Laura Ghanem,
  • Lorena Oliveira Fonseca,
  • Stephen K. Tyring

摘要

Background

Icotrokinra represents a novel therapeutic approach that may address limitations associated with current injectable biologic therapies, including storage requirements and self-administration complexity, and may benefit patients who have needle aversion.

Methods

We included five randomized controlled trials (RCTs) comparing icotrokinra with placebo. PubMed, Embase, and Cochrane CENTRAL were systematically searched from inception to November 2025. Primary outcomes included the proportion of patients achieving an Investigator’s Global Assessment (IGA) score of 0 (clear skin) or 1 (minimal disease) and an IGA score of 0 at weeks 4, 8 and 16; a scalp-specific IGA (ss-IGA) score of 0 or 1 at weeks 8 and 16; and at least 75%, 90%, and 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI 75, PASI 90, and PASI 100) at weeks 4, 8 and 16. Patient-reported outcomes included the Psoriasis Symptoms and Signs Diary (PSSD) symptom score of 0 at weeks 8 and 16. Safety outcomes were also assessed. Secondary analyses involved subgroup evaluations of icotrokinra 200 mg once daily.

Results

Across five included RCTs, 1509 (54.77%) patients received icotrokinra. Icotrokinra significantly increased the likelihood of achieving an IGA score of 0 or1 at week 4 (OR 7.08; 95% CI 4.33 to 11.55; P < 0.001), week 8 (OR 13.29; 95% CI 9.19 to 19.21; P < 0.001), and week 16 (OR 18.76; 95% CI 13.88 to 25.36; P < 0.001). Consistent findings were observed for PASI 90 at week 4 (OR 10.30; 95% CI 2.54 to 41.81; P = 0.003), week 8 (OR 28.65; 95% CI 11.60 to 70.75; P < 0.001),and week 16 (OR 27.14; 95% CI 16.66 to 44.22; P < 0.001). For high-impact, difficult-to-treat sites, icotrokinra significantly increased the likelihood of achieving a ss-IGA score of 0 or 1 at week 8 (OR 7.56; 95% CI 5.73 to 9.96; P < 0.001) and week 16 (OR 9.61; 95% CI 7.00 to 13.20; P < 0.001). Neither the incidence of serious adverse events (OR 0.63; 95% CI 0.29 to 1.34; P = 0.23) nor malignancy (OR 2.61; 95% CI 0.30 to 22.56; P = 0.82) was significantly different between groups.

Conclusions

Icotrokinra demonstrated a favorable short-term efficacy and an acceptable safety profile compared to placebo in patients with moderate-to-severe plaque psoriasis, including meaningful responses in high-impact sites, supporting its potential as a promising oral therapeutic option. Long-term studies and comparative trials against current injectable biologic therapies are warranted to better define its place in the therapeutic armamentarium.